
Cottonbro Studio
According to a recent Marijuana Moment article, the FDA has released its first-ever draft guidance for conducting research on psychedelic substances. The move comes just days after a group of congressional lawmakers filed a bill urging the FDA to do so. The draft guidance is intended to assist researchers in designing clinical trials to explore the therapeutic potential of psychedelic drugs, including substances like psilocybin and MDMA.